Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5585089 | WYETH PHARMS INC | Humanized immunoglobulins |
Dec, 2013
(10 years ago) | |
US5606040 | WYETH PHARMS INC | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
Feb, 2014
(10 years ago) | |
US5693762 | WYETH PHARMS INC | Humanized immunoglobulins |
Dec, 2014
(9 years ago) | |
US5739116 | WYETH PHARMS INC | Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents |
Apr, 2015
(9 years ago) | |
US5767285 | WYETH PHARMS INC | Linkers useful for the synthesis of conjugates of methyltrithio antitumor agents |
Jun, 2015
(8 years ago) | |
US5773001 | WYETH PHARMS INC | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
Jun, 2015
(8 years ago) |
Market Authorisation Date: 17 May, 2000
Treatment: Inhibiting or eliminating acute myeloid leukemia
Dosage: INJECTABLE;INJECTION